Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 4, 2017, Pages 271-279

  Carlsson, Lena M S ^a   Sjöholm, Kajsa ^a   Karlsson, Cecilia ^a,b   Jacobson, Peter ^a   Andersson Assarsson, Johanna C ^a   Svensson, Per Arne ^a   Larsson, Ingrid ^a,c   Hjorth, Stephan ^a   Neovius, Martin ^d   Taube, Magdalena ^a   Carlsson, Björn ^a,b   Peltonen, Markku ^e  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ADULT; ARTICLE; BARIATRIC SURGERY; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PATIENT CARE; QUESTIONNAIRE; RISK REDUCTION; DIABETIC COMPLICATION; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; SWEDEN; VASCULAR DISEASE;

ADULT; BARIATRIC SURGERY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; MALE; MICROVESSELS; MIDDLE AGED; OBESITY; POSTOPERATIVE COMPLICATIONS; PREDIABETIC STATE; SWEDEN; VASCULAR DISEASES;

EID: 85013455468     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30061-X     Document Type: Article

References (34)

1. 1 Nathan, DM, Diabetes: advances in diagnosis and treatment. JAMA 314 (2015), 1052–1062.
2. 2 NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387 (2016), 1513–1530.
3. 3 Guariguata, L, Whiting, DR, Hambleton, I, Beagley, J, Linnenkamp, U, Shaw, JE, Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103 (2014), 137–149.
4. 4 Menke, A, Casagrande, S, Geiss, L, Cowie, CC, Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 314 (2015), 1021–1029.
5. 5 Ligthart, S, van Herpt, TT, Leening, MJ, et al. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol 4 (2016), 44–51.
6. 6 Rahman, S, Rahman, T, Ismail, AA, Rashid, AR, Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab 9 (2007), 767–780.
7. 7 Nathan, DM, Long-term complications of diabetes mellitus. N Engl J Med 328 (1993), 1676–1685.
8. 8 Ryden, L, Mellbin, L, Glucose perturbations and cardiovascular risk: challenges and opportunities. Diab Vasc Dis Res 9 (2012), 170–176.
9. 9 Holman, RR, Paul, SK, Bethel, MA, Matthews, DR, Neil, HA, 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
10. 10 Holman, RR, Sourij, H, Califf, RM, Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383 (2014), 2008–2017.
11. 11 Stratton, IM, Adler, AI, Neil, HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000), 405–412.
12. 12 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20 (1997), 1183–1197.
13. 13 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
14. 14 Ismail-Beigi, F, Craven, T, Banerji, MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376 (2010), 419–430.
15. 15 Patel, A, MacMahon, S, Chalmers, J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
16. 16 Look Ahead Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2 (2014), 801–809.
17. 17 Sjöström, L, Peltonen, M, Jacobson, P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311 (2014), 2297–2304.
18. 18 Dixon, JB, O'Brien, PE, Playfair, J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299 (2008), 316–323.
19. 19 Mingrone, G, Panunzi, S, De Gaetano, A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386 (2015), 964–973.
20. 20 Schauer, PR, Bhatt, DL, Kirwan, JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med 370 (2014), 2002–2013.
21. 21 Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 3 (2015), 866–875.
22. 22 Carlsson, LM, Peltonen, M, Ahlin, S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 367 (2012), 695–704.
23. 23 Sjöström, L, Lindroos, AK, Peltonen, M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351 (2004), 2683–2693.
24. 24 Waaler, HT, Height, weight and mortality. The Norwegian experience. Acta Med Scand Suppl 679 (1984), 1–56.
25. 25 Chamberlain, JJ, Rhinehart, AS, Shaefer, CF Jr, Neuman, A, Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med 164 (2016), 542–552.
26. 26 Buse, JB, Caprio, S, Cefalu, WT, et al. How do we define cure of diabetes?. Diabetes Care 32 (2009), 2133–2135.
27. 27 Chen, Y, Corsino, L, Shantavasinkul, PC, et al. Gastric bypass surgery leads to long-term remission or improvement of type 2 diabetes and significant decrease of microvascular and macrovascular complications. Ann Surg 263 (2016), 1138–1142.
28. 28 Coleman, KJ, Haneuse, S, Johnson, E, et al. Long-term microvascular disease outcomes in patients with type 2 diabetes after bariatric surgery: evidence for the legacy effect of surgery. Diabetes Care 39 (2016), 1400–1407.
29. 29 Gong, Q, Gregg, EW, Wang, J, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia 54 (2011), 300–307.
30. 30 DeFronzo, RA, Abdul-Ghani, MA, Preservation of beta-cell function: the key to diabetes prevention. J Clin Endocrinol Metab 96 (2011), 2354–2366.
31. 31 International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract 104 (2014), 1–52.
32. 32 American Diabetes Association. 4. Prevention or delay of type 2 diabetes. Diabetes Care 39:suppl 1 (2016), S36–S38.
33. 33 Ludvigsson, JF, Andersson, E, Ekbom, A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health, 11, 2011, 450.
34. 34 Fruhbeck, G, Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat Rev Endocrinol 11 (2015), 465–477.